Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19919294 | 0.80 | NOS1 (0.33) | NOS1ALDH1A1CYP3A4MAPTCYP2D6 | |
| SCHEMBL19443166 | 0.71 | — | — | |
| SCHEMBL9153704 | 0.69 | — | — | |
| Biguanide SCHEMBL27454502 | 0.68 | — | — | |
| SCHEMBL22728570 | 0.68 | — | — | |
| Biguanide SCHEMBL18255803 | 0.67 | MAPK1 (0.31) | NOS1 | |
| Biguanide SCHEMBL8039 | 0.67 | — | — | |
| Biguanide SCHEMBL27532476 | 0.65 | MAPK1 (0.33) | NOS1ALDH1A1CYP3A4MAPTCYP2D6 | |
| Biguanide SCHEMBL27599610 | 0.65 | MAPK1 (0.33) | NOS1 | |
| SCHEMBL10819637 | 0.65 | CYP1A2 (0.39) | NOS1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426745-B2 | Polymeric metformin and its use as a therapeutic agent and as a delivery vehicle | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180055792-A1 | Polymeric Metformin And Its Use As A Therapeutic Agent And As A Delivery Vehicle | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426745-B2 | Polymeric metformin and its use as a therapeutic agent and as a delivery vehicle | SLC2A8, SLC2A4, SLC2A1 | NOS1 2551/4885ALDH1A1 4111/4885CYP3A4 3843/4885 |
| US-20180055792-A1 | Polymeric Metformin And Its Use As A Therapeutic Agent And As A Delivery Vehicle | SLC2A8, SLC2A4, SLC2A1 | NOS1 2551/4885ALDH1A1 4111/4885CYP3A4 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.